<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02760264</url>
  </required_header>
  <id_info>
    <org_study_id>VBP15-002</org_study_id>
    <secondary_id>1R44NS095423-01</secondary_id>
    <secondary_id>1U34AR068616-01</secondary_id>
    <nct_id>NCT02760264</nct_id>
  </id_info>
  <brief_title>A Study to Assess Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)</brief_title>
  <official_title>A Phase IIa Open-Label, Multiple Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Exploratory Efficacy of Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ReveraGen BioPharma, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Pittsburgh</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute of Neurological Disorders and Stroke (NINDS)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cooperative International Neuromuscular Research Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>ReveraGen BioPharma, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether a new medication called vamorolone is safe
      and well-tolerated by boys with Duchenne muscular dystrophy (DMD) ages ≥ 4 and &lt; 7 years old.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will evaluate the safety and tolerability of a new steroid-like medication called
      vamorolone in boys with DMD ages ≥ 4 years and &lt; 7 years. Enrolled participants will take the
      study medication for 14 days followed by a 14 day follow-up period. The potential
      effectiveness of vamorolone in treating DMD will also be explored.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2016</start_date>
  <completion_date type="Actual">May 1, 2018</completion_date>
  <primary_completion_date type="Actual">May 1, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Summary of Adverse Events as Assessed by CTCAE Version 4.03</measure>
    <time_frame>Adverse events will be recorded from the date of informed consent and through the time of the subject's last study visit. Serious adverse events will be recorded from the date of informed consent and for up to 30 days after final drug administration.</time_frame>
    <description>Treatment-emergent adverse events (TEAEs) are defined as any adverse event or worsening of an existing conditions after initiation of the investigational product and through the subject's last study visit (study completion or early termination). Serious adverse events were recorded for up to 30 days after the final administration of study drug.
Note: Total Number of Treatment Emergent Adverse Events: The total incidences of TEAEs experienced in study; Any Treatment Emergent Adverse Event: TEAEs reported at least once per dose group</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum Pharmacodynamic Biomarkers (Insulin Resistance)- Fasting Glucose</measure>
    <time_frame>Baseline, Week 2</time_frame>
    <description>Pharmacodynamic biomarkers were measured to investigate the effects of single and multiple oral doses of vamorolone on serum PD biomarkers in ambulant boys ages 4-&lt; 7 years with DMD.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Pharmacodynamic Biomarkers (Insulin Resistance) -Fasting Glucose</measure>
    <time_frame>Baseline, Week 2</time_frame>
    <description>Pharmacodynamic biomarkers were measured to investigate the effects of single and multiple oral doses of vamorolone on serum PD biomarkers in ambulant boys ages 4-&lt; 7 years with DMD.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Pharmacodynamic Biomarkers (Insulin Resistance)- Insulin</measure>
    <time_frame>Baseline , Week 2</time_frame>
    <description>Pharmacodynamic biomarkers were measured to investigate the effects of single and multiple oral doses of vamorolone on serum PD biomarkers in ambulant boys ages 4-&lt; 7 years with DMD.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Pharmacodynamic Biomarkers (Insulin Resistance)- Insulin</measure>
    <time_frame>Baseline, Week 2</time_frame>
    <description>Pharmacodynamic biomarkers were measured to investigate the effects of single and multiple oral doses of vamorolone on serum PD biomarkers in ambulant boys ages 4-&lt; 7 years with DMD.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Pharmacodynamic Biomarkers (Adrenal Axis Suppression)- First in Morning Cortisol</measure>
    <time_frame>Week 2 (pre-dose)</time_frame>
    <description>Pharmacodynamic biomarkers were measured to investigate the effects of single and multiple oral doses of vamorolone on serum PD biomarkers in ambulant boys ages 4-&lt; 7 years with DMD.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Pharmacodynamics Biomarkers (Bone Turnover) -Osteocalcin</measure>
    <time_frame>Baseline, Day 1, Week 2, Week 4</time_frame>
    <description>Pharmacodynamic biomarkers were measured to investigate the effects of single and multiple oral doses of vamorolone on serum PD biomarkers in ambulant boys ages 4-&lt; 7 years with DMD.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Pharmacodynamic Biomarkers (Bone Turnover)- Procollagen 1 N-Terminal Propeptide</measure>
    <time_frame>Baseline Day 1 Week 2 Week 4</time_frame>
    <description>Pharmacodynamic biomarkers were measured to investigate the effects of single and multiple oral doses of vamorolone on serum PD biomarkers in ambulant boys ages 4-&lt; 7 years with DMD.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Pharmacodynamic Biomarkers (Bone Turnover)- Procollagen 1 N-Terminal Propeptide</measure>
    <time_frame>Baseline, Day 1, Week 2, Week 4</time_frame>
    <description>Pharmacodynamic biomarkers were measured to investigate the effects of single and multiple oral doses of vamorolone on serum PD biomarkers in ambulant boys ages 4-&lt; 7 years with DMD.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Pharmacodynamic Biomarkers (Bone Turnover)-Type I Collagen C-Telopeptides</measure>
    <time_frame>Baseline, Day 1, Week 4</time_frame>
    <description>Pharmacodynamic biomarkers were measured to investigate the effects of single and multiple oral doses of vamorolone on serum PD biomarkers in ambulant boys ages 4-&lt; 7 years with DMD.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic (PK) Assessments (Tmax)</measure>
    <time_frame>Day 1, Week 2</time_frame>
    <description>Plasma concentrations of vamorolone were measured using a specific and validated liquid chromatography tandem mass spectrometry (LC-MS) assay. tmax= time when plasma concentration is at maximum.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic (PK) Assessments (AUC Inf)</measure>
    <time_frame>Day 1, Week 2</time_frame>
    <description>Plasma concentrations of vamorolone were measured using a specific and validated liquid chromatography tandem mass spectrometry (LC-MS) assay. AUC inf= Area under the concentration vs. time curve to time infinity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic (PK) Assessments CL (ml/hr/kg)</measure>
    <time_frame>Day 1, Week 2</time_frame>
    <description>Plasma concentrations of vamorolone were measured using a specific and validated liquid chromatography tandem mass spectrometry (LC-MS) assay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic (PK) Assessments t(1/2)</measure>
    <time_frame>Day 1, Week 2</time_frame>
    <description>Plasma concentrations of vamorolone were measured using a specific and validated liquid chromatography tandem mass spectrometry (LC-MS) assay. t1/2= elimination half life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic (PK) Assessments (Cmax)</measure>
    <time_frame>Day 1, Week 2</time_frame>
    <description>Plasma concentrations of vamorolone were measured using a specific and validated liquid chromatography tandem mass spectrometry (LC-MS) assay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Metabolites in Safety Testing (MIST) Assessment</measure>
    <time_frame>Week 2 (Day 14)</time_frame>
    <description>A portion of each blood sample of the Week 2 (Day 14) pharmacokinetic assessment time points for the subjects receiving vamorolone 2 mg/kg/day was used for analysis of vamorolone metabolites.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Duchenne Muscular Dystrophy</condition>
  <arm_group>
    <arm_group_label>Dose Level Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants enrolled in Dose Level Group 1 will receive vamorolone 0.25 mg/kg/day.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Level Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants enrolled in Dose Level Group 2 will receive vamorolone 0.75 mg/kg/day.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Level Group 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants enrolled in Dose Level Group 3 will receive vamorolone 2.0 mg/kg/day.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Level Group 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants enrolled in Dose Level Group 4 will receive vamorolone 6.0 mg/kg/day.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vamorolone 0.25 mg/kg/day</intervention_name>
    <description>Oral administration of 0.25 mg/kg/day daily for 14 days.</description>
    <arm_group_label>Dose Level Group 1</arm_group_label>
    <other_name>VBP15</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vamorolone 0.75 mg/kg/day</intervention_name>
    <description>Oral administration of 0.75 mg/kg/day daily for 14 days.</description>
    <arm_group_label>Dose Level Group 2</arm_group_label>
    <other_name>VBP15</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vamorolone 2.0 mg/kg/day</intervention_name>
    <description>Oral administration of 2.0 mg/kg/day daily for 14 days.</description>
    <arm_group_label>Dose Level Group 3</arm_group_label>
    <other_name>VBP15</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vamorolone 6.0 mg/kg/day</intervention_name>
    <description>Oral administration of 6 mg/kg/day daily for 14 days.</description>
    <arm_group_label>Dose Level Group 4</arm_group_label>
    <other_name>VBP15</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subject's parent or legal guardian has provided written informed consent/Health
             Insurance Portability and Accountability Act (HIPAA) authorization prior to any
             study-related procedures;

          2. Subject has a confirmed (by Central Genetic Counselor) diagnosis of DMD as defined as:

               1. Dystrophin immunofluorescence and/or immunoblot showing complete dystrophin
                  deficiency, and clinical picture consistent with typical DMD, OR

               2. Identifiable mutation within the DMD gene (deletion/duplication of one or more
                  exons) where reading frame can be predicted as 'out-of-frame', and clinical
                  picture consistent with typical DMD, OR

               3. Complete dystrophin gene sequencing showing an alteration (point mutation,
                  duplication, other) that is expected to preclude production of the dystrophin
                  protein (i.e. nonsense mutation, deletion/duplication leading to a downstream
                  stop codon), with a typical clinical picture of DMD;

          3. Subject is ≥ 4 years and &lt; 7 years of age at time of enrollment in the study;

          4. Subject is able to complete the Time to Stand Test (TTSTAND) without assistance, as
             assessed at the Screening and Baseline Visits;

          5. Clinical laboratory test results are within the normal range at the Screening Visit,
             or if abnormal, are not clinically significant, in the opinion of the Investigator.
             (Note: Serum gamma glutamyl transferase [GGT], creatinine, and total bilirubin all
             must be ≤ upper limit of the normal range at the Screening Visit);

          6. Subject has evidence of chicken pox immunity as determined by presence of IgG
             antibodies to varicella, as documented by a positive test result from the testing
             laboratory at the Screening Visit; and

          7. Subject and parent/guardian are willing and able to comply with scheduled visits,
             study drug administration plan, and study procedures.

        Exclusion Criteria:

          1. Subject has current or history of major renal or hepatic impairment, diabetes mellitus
             or immunosuppression;

          2. Subject has current or history of chronic systemic fungal or viral infections;

          3. Subject has had an acute illness within 4 weeks prior to the first dose of study
             medication;

          4. Subject has used mineralocorticoid receptor agents, such as spironolactone,
             eplerenone, canrenone (canrenoate potassium), prorenone (prorenoate potassium),
             mexrenone (mexrenoate potassium) within 4 weeks prior to the first dose of study
             medication;

          5. Subject has evidence of symptomatic cardiomyopathy. [Note: Asymptomatic cardiac
             abnormality on investigation would not be exclusionary];

          6. Subject is currently being treated or has received previous treatment with oral
             glucocorticoids or other immunosuppressive agents. [Notes: Past transient use of oral
             glucocorticoids or other oral immunosuppressive agents for no longer than 3 months
             cumulative, with last use at least 3 months prior to first dose of study medication,
             will be considered for eligibility on a case-by-case basis. Inhaled and/or topical
             corticosteroids prescribed for an indication other than DMD are permitted but must be
             administered at stable dose for at least 3 months prior to study drug administration];

          7. Subject has used idebenone within 4 weeks prior to the first dose of study medication;

          8. Subject has an allergy or hypersensitivity to the study medication or to any of its
             constituents;

          9. Subject has severe behavioral or cognitive problems that preclude participation in the
             study, in the opinion of the Investigator;

         10. Subject has previous or ongoing medical condition, medical history, physical findings
             or laboratory abnormalities that could affect safety, make it unlikely that treatment
             and follow-up will be correctly completed or impair the assessment of study results,
             in the opinion of the Investigator;

         11. Subject is taking any other investigational drug currently or has taken any other
             investigational drug within 3 months prior to the start of study treatment; or

         12. Subject has previously been enrolled in the study.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>4 Years</minimum_age>
    <maximum_age>6 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paula R Clemens, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Pittsburgh</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California Davis</name>
      <address>
        <city>Davis</city>
        <state>California</state>
        <zip>95616</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Florida</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nemours Children's Hospital</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32827</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ann &amp; Robert H. Lurie Children's Hospital</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas Southwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Children's Hospital</name>
      <address>
        <city>Melbourne</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sydney Children's Hospital</name>
      <address>
        <city>Westmead</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alberta Children's Hospital</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T3B 6A8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Schneider Children's Medical Center</name>
      <address>
        <city>Petah Tikvah</city>
        <zip>49202</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Queen Silvia Children's Hospital</name>
      <address>
        <city>Gothenburg</city>
        <zip>41685</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Newcastle upon Tyne Hospitals NHS Foundation Trust</name>
      <address>
        <city>Newcastle upon Tyne</city>
        <zip>NE7 7DN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Canada</country>
    <country>Israel</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://cinrgresearch.org/</url>
    <description>Cooperative International Research Group</description>
  </link>
  <link>
    <url>http://www.reveragen.com/</url>
    <description>ReveraGen BioPharma, Inc</description>
  </link>
  <link>
    <url>https://www.ncbi.nlm.nih.gov/pubmed/30219580</url>
    <description>Phase IIa trial in Duchenne muscular dystrophy shows vamorolone is a first-in-class dissociative steroidal anti-inflammatory drug.</description>
  </link>
  <verification_date>December 2018</verification_date>
  <study_first_submitted>April 28, 2016</study_first_submitted>
  <study_first_submitted_qc>April 30, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 3, 2016</study_first_posted>
  <results_first_submitted>September 28, 2018</results_first_submitted>
  <results_first_submitted_qc>December 11, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">January 2, 2019</results_first_posted>
  <last_update_submitted>December 11, 2018</last_update_submitted>
  <last_update_submitted_qc>December 11, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 2, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Duchenne Muscular Dystrophy</keyword>
  <keyword>vamorolone</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Muscular Dystrophies</mesh_term>
    <mesh_term>Muscular Dystrophy, Duchenne</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>January 20, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/64/NCT02760264/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>January 31, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/64/NCT02760264/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Vamorolone 0.25 mg/kg/Day</title>
          <description>Participants enrolled in Dose Level Group 1 will receive vamorolone 0.25 mg/kg/day.
Oral administration of 0.25 mg/kg/day daily for 14 days.</description>
        </group>
        <group group_id="P2">
          <title>Vamorolone 0.75 mg/kg/Day</title>
          <description>Participants enrolled in Dose Level Group 2 will receive vamorolone 0.75 mg/kg/day.
Oral administration of 0.75 mg/kg/day daily for 14 days.</description>
        </group>
        <group group_id="P3">
          <title>Vamorolone 2.0 mg/kg/Day</title>
          <description>Participants enrolled in Dose Level Group 3 will receive vamorolone 2.0 mg/kg/day.
Oral administration of 2.0 mg/kg/day daily for 14 days.</description>
        </group>
        <group group_id="P4">
          <title>Vamorolone 6.0 mg/kg/Day</title>
          <description>Participants enrolled in Dose Level Group 4 will receive vamorolone 6.0 mg/kg/day.
Oral administration of 6 mg/kg/day daily for 14 days.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>0.25 mg/kg/Day</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>0.75 mg/kg/Day</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>2.0 mg/kg/Day</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="12"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="12"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>6.0 mg/kg/Day</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Dose Level Group 1</title>
          <description>Participants enrolled in Dose Level Group 1 will receive vamorolone 0.25 mg/kg/day.
Vamorolone 0.25 mg/kg/day: Oral administration of 0.25 mg/kg/day daily for 14 days.</description>
        </group>
        <group group_id="B2">
          <title>Dose Level Group 2</title>
          <description>Participants enrolled in Dose Level Group 2 will receive vamorolone 0.75 mg/kg/day.
Vamorolone 0.75 mg/kg/day: Oral administration of 0.75 mg/kg/day daily for 14 days.</description>
        </group>
        <group group_id="B3">
          <title>Dose Level Group 3</title>
          <description>Participants enrolled in Dose Level Group 3 will receive vamorolone 2.0 mg/kg/day.
Vamorolone 2.0 mg/kg/day: Oral administration of 2.0 mg/kg/day daily for 14 days.</description>
        </group>
        <group group_id="B4">
          <title>Dose Level Group 4</title>
          <description>Participants enrolled in Dose Level Group 4 will receive vamorolone 6.0 mg/kg/day.
Vamorolone 6.0 mg/kg/day: Oral administration of 6 mg/kg/day daily for 14 days.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
            <count group_id="B2" value="12"/>
            <count group_id="B3" value="12"/>
            <count group_id="B4" value="12"/>
            <count group_id="B5" value="48"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Age</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5.2" spread="1.03"/>
                    <measurement group_id="B2" value="4.8" spread="0.83"/>
                    <measurement group_id="B3" value="4.7" spread="0.89"/>
                    <measurement group_id="B4" value="4.8" spread="0.75"/>
                    <measurement group_id="B5" value="4.9" spread="0.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="12"/>
                    <measurement group_id="B5" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="9"/>
                    <measurement group_id="B5" value="44"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="12"/>
                    <measurement group_id="B5" value="45"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sweden</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United Kingdom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Israel</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Australia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Overall Summary of Adverse Events as Assessed by CTCAE Version 4.03</title>
        <description>Treatment-emergent adverse events (TEAEs) are defined as any adverse event or worsening of an existing conditions after initiation of the investigational product and through the subject's last study visit (study completion or early termination). Serious adverse events were recorded for up to 30 days after the final administration of study drug.
Note: Total Number of Treatment Emergent Adverse Events: The total incidences of TEAEs experienced in study; Any Treatment Emergent Adverse Event: TEAEs reported at least once per dose group</description>
        <time_frame>Adverse events will be recorded from the date of informed consent and through the time of the subject's last study visit. Serious adverse events will be recorded from the date of informed consent and for up to 30 days after final drug administration.</time_frame>
        <population>Safety Population: All subjects who receive at least one dose of vamorolone study medication will be included in safety population.</population>
        <group_list>
          <group group_id="O1">
            <title>Dose Level Group 1</title>
            <description>Participants enrolled in Dose Level Group 1 will receive vamorolone 0.25 mg/kg/day.
Vamorolone 0.25 mg/kg/day: Oral administration of 0.25 mg/kg/day daily for 14 days.</description>
          </group>
          <group group_id="O2">
            <title>Dose Level Group 2</title>
            <description>Participants enrolled in Dose Level Group 2 will receive vamorolone 0.75 mg/kg/day.
Vamorolone 0.75 mg/kg/day: Oral administration of 0.75 mg/kg/day daily for 14 days.</description>
          </group>
          <group group_id="O3">
            <title>Dose Level Group 3</title>
            <description>Participants enrolled in Dose Level Group 3 will receive vamorolone 2.0 mg/kg/day.
Vamorolone 2.0 mg/kg/day: Oral administration of 2.0 mg/kg/day daily for 14 days.</description>
          </group>
          <group group_id="O4">
            <title>Dose Level Group 4</title>
            <description>Participants enrolled in Dose Level Group 4 will receive vamorolone 6.0 mg/kg/day.
Vamorolone 6.0 mg/kg/day: Oral administration of 6 mg/kg/day daily for 14 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Summary of Adverse Events as Assessed by CTCAE Version 4.03</title>
          <description>Treatment-emergent adverse events (TEAEs) are defined as any adverse event or worsening of an existing conditions after initiation of the investigational product and through the subject's last study visit (study completion or early termination). Serious adverse events were recorded for up to 30 days after the final administration of study drug.
Note: Total Number of Treatment Emergent Adverse Events: The total incidences of TEAEs experienced in study; Any Treatment Emergent Adverse Event: TEAEs reported at least once per dose group</description>
          <population>Safety Population: All subjects who receive at least one dose of vamorolone study medication will be included in safety population.</population>
          <units>Number of Events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Total Number of Adverse Events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="18"/>
                    <measurement group_id="O3" value="13"/>
                    <measurement group_id="O4" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Number of Treatment Emergent Adverse Events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="13"/>
                    <measurement group_id="O3" value="11"/>
                    <measurement group_id="O4" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Treatment Emergent Adverse Events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Drug Related Treatment Emergent Adverse Events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any CTCAE Grade 3 or Higher TEAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Discontinuation of Study Drug due to TEAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Serious Treatment Emergent Adverse Events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Death</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum Pharmacodynamic Biomarkers (Insulin Resistance)- Fasting Glucose</title>
        <description>Pharmacodynamic biomarkers were measured to investigate the effects of single and multiple oral doses of vamorolone on serum PD biomarkers in ambulant boys ages 4-&lt; 7 years with DMD.</description>
        <time_frame>Baseline, Week 2</time_frame>
        <population>Safety Population: All subject who receive at least dose of vamorolone study medication will be included in the safety population.</population>
        <group_list>
          <group group_id="O1">
            <title>Dose Level Group 1</title>
            <description>Participants enrolled in Dose Level Group 1 will receive vamorolone 0.25 mg/kg/day.
Vamorolone 0.25 mg/kg/day: Oral administration of 0.25 mg/kg/day daily for 14 days.</description>
          </group>
          <group group_id="O2">
            <title>Dose Level Group 2</title>
            <description>Participants enrolled in Dose Level Group 2 will receive vamorolone 0.75 mg/kg/day.
Vamorolone 0.75 mg/kg/day: Oral administration of 0.75 mg/kg/day daily for 14 days.</description>
          </group>
          <group group_id="O3">
            <title>Dose Level Group 3</title>
            <description>Participants enrolled in Dose Level Group 3 will receive vamorolone 2.0 mg/kg/day.
Vamorolone 2.0 mg/kg/day: Oral administration of 2.0 mg/kg/day daily for 14 days.</description>
          </group>
          <group group_id="O4">
            <title>Dose Level Group 4</title>
            <description>Participants enrolled in Dose Level Group 4 will receive vamorolone 6.0 mg/kg/day.
Vamorolone 6.0 mg/kg/day: Oral administration of 6 mg/kg/day daily for 14 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Pharmacodynamic Biomarkers (Insulin Resistance)- Fasting Glucose</title>
          <description>Pharmacodynamic biomarkers were measured to investigate the effects of single and multiple oral doses of vamorolone on serum PD biomarkers in ambulant boys ages 4-&lt; 7 years with DMD.</description>
          <population>Safety Population: All subject who receive at least dose of vamorolone study medication will be included in the safety population.</population>
          <units>mg/ dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="12"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87.5" spread="9.44"/>
                    <measurement group_id="O2" value="88.9" spread="18.71"/>
                    <measurement group_id="O3" value="89.3" spread="7.91"/>
                    <measurement group_id="O4" value="92.3" spread="8.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="12"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85.3" spread="9.29"/>
                    <measurement group_id="O2" value="83.1" spread="6.69"/>
                    <measurement group_id="O3" value="89.5" spread="5.20"/>
                    <measurement group_id="O4" value="89.2" spread="11.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2 Change from Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="12"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.2" spread="10.46"/>
                    <measurement group_id="O2" value="-5.8" spread="18.92"/>
                    <measurement group_id="O3" value="0.2" spread="8.79"/>
                    <measurement group_id="O4" value="-1.3" spread="9.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Treatment levels were not compared.</non_inferiority_desc>
            <other_analysis_desc>Safety Population was used for this analysis. Safety Population includes all subjects who receive at least one dose of vamorolone study medication.
Treatment levels were not compared.</other_analysis_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum Pharmacodynamic Biomarkers (Insulin Resistance) -Fasting Glucose</title>
        <description>Pharmacodynamic biomarkers were measured to investigate the effects of single and multiple oral doses of vamorolone on serum PD biomarkers in ambulant boys ages 4-&lt; 7 years with DMD.</description>
        <time_frame>Baseline, Week 2</time_frame>
        <population>Safety Population: All subject who receive at least dose of vamorolone study medication will be included in the safety population.</population>
        <group_list>
          <group group_id="O1">
            <title>Dose Level Group 1</title>
            <description>Participants enrolled in Dose Level Group 1 will receive vamorolone 0.25 mg/kg/day.
Vamorolone 0.25 mg/kg/day: Oral administration of 0.25 mg/kg/day daily for 14 days.</description>
          </group>
          <group group_id="O2">
            <title>Dose Level Group 2</title>
            <description>Participants enrolled in Dose Level Group 2 will receive vamorolone 0.75 mg/kg/day.
Vamorolone 0.75 mg/kg/day: Oral administration of 0.75 mg/kg/day daily for 14 days.</description>
          </group>
          <group group_id="O3">
            <title>Dose Level Group 3</title>
            <description>Participants enrolled in Dose Level Group 3 will receive vamorolone 2.0 mg/kg/day.
Vamorolone 2.0 mg/kg/day: Oral administration of 2.0 mg/kg/day daily for 14 days.</description>
          </group>
          <group group_id="O4">
            <title>Dose Level Group 4</title>
            <description>Participants enrolled in Dose Level Group 4 will receive vamorolone 6.0 mg/kg/day.
Vamorolone 6.0 mg/kg/day: Oral administration of 6 mg/kg/day daily for 14 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Pharmacodynamic Biomarkers (Insulin Resistance) -Fasting Glucose</title>
          <description>Pharmacodynamic biomarkers were measured to investigate the effects of single and multiple oral doses of vamorolone on serum PD biomarkers in ambulant boys ages 4-&lt; 7 years with DMD.</description>
          <population>Safety Population: All subject who receive at least dose of vamorolone study medication will be included in the safety population.</population>
          <units>Week 2 % change from Baseline</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.8" spread="13.07"/>
                    <measurement group_id="O2" value="-4.2" spread="13.98"/>
                    <measurement group_id="O3" value="0.8" spread="9.76"/>
                    <measurement group_id="O4" value="-1.2" spread="9.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum Pharmacodynamic Biomarkers (Insulin Resistance)- Insulin</title>
        <description>Pharmacodynamic biomarkers were measured to investigate the effects of single and multiple oral doses of vamorolone on serum PD biomarkers in ambulant boys ages 4-&lt; 7 years with DMD.</description>
        <time_frame>Baseline , Week 2</time_frame>
        <population>Safety Population All subjects who receive at least one dose of vamorolone study medication will be included in the Safety Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Dose Level Group 1</title>
            <description>Participants enrolled in Dose Level Group 1 will receive vamorolone 0.25 mg/kg/day.
Vamorolone 0.25 mg/kg/day: Oral administration of 0.25 mg/kg/day daily for 14 days.</description>
          </group>
          <group group_id="O2">
            <title>Dose Level Group 2</title>
            <description>Participants enrolled in Dose Level Group 2 will receive vamorolone 0.75 mg/kg/day.
Vamorolone 0.75 mg/kg/day: Oral administration of 0.75 mg/kg/day daily for 14 days.</description>
          </group>
          <group group_id="O3">
            <title>Dose Level Group 3</title>
            <description>Participants enrolled in Dose Level Group 3 will receive vamorolone 2.0 mg/kg/day.
Vamorolone 2.0 mg/kg/day: Oral administration of 2.0 mg/kg/day daily for 14 days.</description>
          </group>
          <group group_id="O4">
            <title>Dose Level Group 4</title>
            <description>Participants enrolled in Dose Level Group 4 will receive vamorolone 6.0 mg/kg/day.
Vamorolone 6.0 mg/kg/day: Oral administration of 6 mg/kg/day daily for 14 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Pharmacodynamic Biomarkers (Insulin Resistance)- Insulin</title>
          <description>Pharmacodynamic biomarkers were measured to investigate the effects of single and multiple oral doses of vamorolone on serum PD biomarkers in ambulant boys ages 4-&lt; 7 years with DMD.</description>
          <population>Safety Population All subjects who receive at least one dose of vamorolone study medication will be included in the Safety Population.</population>
          <units>µIU/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.54" spread="3.651"/>
                    <measurement group_id="O2" value="3.09" spread="2.033"/>
                    <measurement group_id="O3" value="3.40" spread="1.548"/>
                    <measurement group_id="O4" value="3.96" spread="2.027"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.29" spread="2.671"/>
                    <measurement group_id="O2" value="3.22" spread="1.924"/>
                    <measurement group_id="O3" value="3.87" spread="2.118"/>
                    <measurement group_id="O4" value="6.73" spread="4.599"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2 Change from Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.65" spread="2.913"/>
                    <measurement group_id="O2" value="0.34" spread="1.289"/>
                    <measurement group_id="O3" value="0.47" spread="2.777"/>
                    <measurement group_id="O4" value="2.78" spread="4.651"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Treatment levels were not compared.</non_inferiority_desc>
            <other_analysis_desc>Safety Population was used for this analysis. Safety Population includes all subjects who receive at least one dose of vamorolone study medication.
Treatment levels were not compared.</other_analysis_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum Pharmacodynamic Biomarkers (Insulin Resistance)- Insulin</title>
        <description>Pharmacodynamic biomarkers were measured to investigate the effects of single and multiple oral doses of vamorolone on serum PD biomarkers in ambulant boys ages 4-&lt; 7 years with DMD.</description>
        <time_frame>Baseline, Week 2</time_frame>
        <population>Safety Population All subjects who receive at least one dose of vamorolone study medication will be included in the Safety Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Dose Level Group 1</title>
            <description>Participants enrolled in Dose Level Group 1 will receive vamorolone 0.25 mg/kg/day.
Vamorolone 0.25 mg/kg/day: Oral administration of 0.25 mg/kg/day daily for 14 days.</description>
          </group>
          <group group_id="O2">
            <title>Dose Level Group 2</title>
            <description>Participants enrolled in Dose Level Group 2 will receive vamorolone 0.75 mg/kg/day.
Vamorolone 0.75 mg/kg/day: Oral administration of 0.75 mg/kg/day daily for 14 days.</description>
          </group>
          <group group_id="O3">
            <title>Dose Level Group 3</title>
            <description>Participants enrolled in Dose Level Group 3 will receive vamorolone 2.0 mg/kg/day.
Vamorolone 2.0 mg/kg/day: Oral administration of 2.0 mg/kg/day daily for 14 days.</description>
          </group>
          <group group_id="O4">
            <title>Dose Level Group 4</title>
            <description>Participants enrolled in Dose Level Group 4 will receive vamorolone 6.0 mg/kg/day.
Vamorolone 6.0 mg/kg/day: Oral administration of 6 mg/kg/day daily for 14 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Pharmacodynamic Biomarkers (Insulin Resistance)- Insulin</title>
          <description>Pharmacodynamic biomarkers were measured to investigate the effects of single and multiple oral doses of vamorolone on serum PD biomarkers in ambulant boys ages 4-&lt; 7 years with DMD.</description>
          <population>Safety Population All subjects who receive at least one dose of vamorolone study medication will be included in the Safety Population.</population>
          <units>Week 2 % change from Baseline</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.54" spread="32.622"/>
                    <measurement group_id="O2" value="26.07" spread="76.483"/>
                    <measurement group_id="O3" value="42.85" spread="107.337"/>
                    <measurement group_id="O4" value="83.55" spread="117.064"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum Pharmacodynamic Biomarkers (Adrenal Axis Suppression)- First in Morning Cortisol</title>
        <description>Pharmacodynamic biomarkers were measured to investigate the effects of single and multiple oral doses of vamorolone on serum PD biomarkers in ambulant boys ages 4-&lt; 7 years with DMD.</description>
        <time_frame>Week 2 (pre-dose)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Dose Level Group 1</title>
            <description>Participants enrolled in Dose Level Group 1 will receive vamorolone 0.25 mg/kg/day.
Vamorolone 0.25 mg/kg/day: Oral administration of 0.25 mg/kg/day daily for 14 days.</description>
          </group>
          <group group_id="O2">
            <title>Dose Level Group 2</title>
            <description>Participants enrolled in Dose Level Group 2 will receive vamorolone 0.75 mg/kg/day.
Vamorolone 0.75 mg/kg/day: Oral administration of 0.75 mg/kg/day daily for 14 days.</description>
          </group>
          <group group_id="O3">
            <title>Dose Level Group 3</title>
            <description>Participants enrolled in Dose Level Group 3 will receive vamorolone 2.0 mg/kg/day.
Vamorolone 2.0 mg/kg/day: Oral administration of 2.0 mg/kg/day daily for 14 days.</description>
          </group>
          <group group_id="O4">
            <title>Dose Level Group 4</title>
            <description>Participants enrolled in Dose Level Group 4 will receive vamorolone 6.0 mg/kg/day.
Vamorolone 6.0 mg/kg/day: Oral administration of 6 mg/kg/day daily for 14 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Pharmacodynamic Biomarkers (Adrenal Axis Suppression)- First in Morning Cortisol</title>
          <description>Pharmacodynamic biomarkers were measured to investigate the effects of single and multiple oral doses of vamorolone on serum PD biomarkers in ambulant boys ages 4-&lt; 7 years with DMD.</description>
          <units>mcg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="11"/>
                <count group_id="O4" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.425" spread="1.7358"/>
                    <measurement group_id="O2" value="9.755" spread="2.7614"/>
                    <measurement group_id="O3" value="7.321" spread="3.0322"/>
                    <measurement group_id="O4" value="3.010" spread="1.0141"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Treatment levels were not compared.</non_inferiority_desc>
            <other_analysis_desc>Safety Population was used for this analysis. Safety Population includes all subjects who receive at least one dose of vamorolone study medication.
Treatment levels were not compared.</other_analysis_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum Pharmacodynamics Biomarkers (Bone Turnover) -Osteocalcin</title>
        <description>Pharmacodynamic biomarkers were measured to investigate the effects of single and multiple oral doses of vamorolone on serum PD biomarkers in ambulant boys ages 4-&lt; 7 years with DMD.</description>
        <time_frame>Baseline, Day 1, Week 2, Week 4</time_frame>
        <population>Safety Population: All subjects who receive at least one dose of vamorolone study medication will be included in the Safety Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Dose Level Group 1</title>
            <description>Participants enrolled in Dose Level Group 1 will receive vamorolone 0.25 mg/kg/day.
Vamorolone 0.25 mg/kg/day: Oral administration of 0.25 mg/kg/day daily for 14 days.</description>
          </group>
          <group group_id="O2">
            <title>Dose Level Group 2</title>
            <description>Participants enrolled in Dose Level Group 2 will receive vamorolone 0.75 mg/kg/day.
Vamorolone 0.75 mg/kg/day: Oral administration of 0.75 mg/kg/day daily for 14 days.</description>
          </group>
          <group group_id="O3">
            <title>Dose Level Group 3</title>
            <description>Participants enrolled in Dose Level Group 3 will receive vamorolone 2.0 mg/kg/day.
Vamorolone 2.0 mg/kg/day: Oral administration of 2.0 mg/kg/day daily for 14 days.</description>
          </group>
          <group group_id="O4">
            <title>Dose Level Group 4</title>
            <description>Participants enrolled in Dose Level Group 4 will receive vamorolone 6.0 mg/kg/day.
Vamorolone 6.0 mg/kg/day: Oral administration of 6 mg/kg/day daily for 14 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Pharmacodynamics Biomarkers (Bone Turnover) -Osteocalcin</title>
          <description>Pharmacodynamic biomarkers were measured to investigate the effects of single and multiple oral doses of vamorolone on serum PD biomarkers in ambulant boys ages 4-&lt; 7 years with DMD.</description>
          <population>Safety Population: All subjects who receive at least one dose of vamorolone study medication will be included in the Safety Population.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="12"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.94" spread="11.622"/>
                    <measurement group_id="O2" value="35.66" spread="6.800"/>
                    <measurement group_id="O3" value="41.17" spread="5.617"/>
                    <measurement group_id="O4" value="44.36" spread="5.979"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="12"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.37" spread="14.189"/>
                    <measurement group_id="O2" value="35.89" spread="7.526"/>
                    <measurement group_id="O3" value="34.93" spread="6.881"/>
                    <measurement group_id="O4" value="33.52" spread="9.135"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 Change from Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="12"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.43" spread="8.197"/>
                    <measurement group_id="O2" value="0.23" spread="5.304"/>
                    <measurement group_id="O3" value="-6.23" spread="10.930"/>
                    <measurement group_id="O4" value="-11.37" spread="9.137"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="12"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.53" spread="12.025"/>
                    <measurement group_id="O2" value="35.10" spread="8.238"/>
                    <measurement group_id="O3" value="37.51" spread="8.624"/>
                    <measurement group_id="O4" value="29.04" spread="4.853"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2 Change from Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="12"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.58" spread="5.986"/>
                    <measurement group_id="O2" value="-0.56" spread="7.934"/>
                    <measurement group_id="O3" value="-3.66" spread="9.818"/>
                    <measurement group_id="O4" value="-15.32" spread="6.450"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="12"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.20" spread="14.136"/>
                    <measurement group_id="O2" value="42.24" spread="8.426"/>
                    <measurement group_id="O3" value="47.91" spread="6.648"/>
                    <measurement group_id="O4" value="42.81" spread="10.851"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 Change from Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="12"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.26" spread="5.650"/>
                    <measurement group_id="O2" value="6.58" spread="9.341"/>
                    <measurement group_id="O3" value="6.74" spread="9.747"/>
                    <measurement group_id="O4" value="-1.55" spread="11.176"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Treatment levels were not compared.</non_inferiority_desc>
            <other_analysis_desc>Safety Population was used for this analysis. Safety Population includes all subjects who receive at least one dose of vamorolone study medication.
Treatment levels were not compared.</other_analysis_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum Pharmacodynamics Biomarkers (Bone Turnover) -Osteocalcin</title>
        <description>Pharmacodynamic biomarkers were measured to investigate the effects of single and multiple oral doses of vamorolone on serum PD biomarkers in ambulant boys ages 4-&lt; 7 years with DMD.</description>
        <time_frame>Baseline, Day 1, Week 2, Week 4</time_frame>
        <population>Safety Population: All subjects who receive at least one dose of vamorolone study medication will be included in the Safety Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Dose Level Group 1</title>
            <description>Participants enrolled in Dose Level Group 1 will receive vamorolone 0.25 mg/kg/day.
Vamorolone 0.25 mg/kg/day: Oral administration of 0.25 mg/kg/day daily for 14 days.</description>
          </group>
          <group group_id="O2">
            <title>Dose Level Group 2</title>
            <description>Participants enrolled in Dose Level Group 2 will receive vamorolone 0.75 mg/kg/day.
Vamorolone 0.75 mg/kg/day: Oral administration of 0.75 mg/kg/day daily for 14 days.</description>
          </group>
          <group group_id="O3">
            <title>Dose Level Group 3</title>
            <description>Participants enrolled in Dose Level Group 3 will receive vamorolone 2.0 mg/kg/day.
Vamorolone 2.0 mg/kg/day: Oral administration of 2.0 mg/kg/day daily for 14 days.</description>
          </group>
          <group group_id="O4">
            <title>Dose Level Group 4</title>
            <description>Participants enrolled in Dose Level Group 4 will receive vamorolone 6.0 mg/kg/day.
Vamorolone 6.0 mg/kg/day: Oral administration of 6 mg/kg/day daily for 14 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Pharmacodynamics Biomarkers (Bone Turnover) -Osteocalcin</title>
          <description>Pharmacodynamic biomarkers were measured to investigate the effects of single and multiple oral doses of vamorolone on serum PD biomarkers in ambulant boys ages 4-&lt; 7 years with DMD.</description>
          <population>Safety Population: All subjects who receive at least one dose of vamorolone study medication will be included in the Safety Population.</population>
          <units>% change from Baseline</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1 Percent Change from Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="12"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.95" spread="22.015"/>
                    <measurement group_id="O2" value="1.41" spread="15.449"/>
                    <measurement group_id="O3" value="-12.63" spread="25.020"/>
                    <measurement group_id="O4" value="-25.05" spread="20.228"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2 Percent Change from Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="12"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.48" spread="16.756"/>
                    <measurement group_id="O2" value="-0.07" spread="22.408"/>
                    <measurement group_id="O3" value="-7.81" spread="23.664"/>
                    <measurement group_id="O4" value="-33.87" spread="12.548"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 Percent Change from Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="12"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.72" spread="14.063"/>
                    <measurement group_id="O2" value="20.91" spread="28.644"/>
                    <measurement group_id="O3" value="18.74" spread="25.095"/>
                    <measurement group_id="O4" value="-2.43" spread="25.932"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum Pharmacodynamic Biomarkers (Bone Turnover)- Procollagen 1 N-Terminal Propeptide</title>
        <description>Pharmacodynamic biomarkers were measured to investigate the effects of single and multiple oral doses of vamorolone on serum PD biomarkers in ambulant boys ages 4-&lt; 7 years with DMD.</description>
        <time_frame>Baseline Day 1 Week 2 Week 4</time_frame>
        <population>Safety Population: All subjects who receive at least one dose of vamorolone study medication will be included in the Safety Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Dose Level Group 1</title>
            <description>Participants enrolled in Dose Level Group 1 will receive vamorolone 0.25 mg/kg/day.
Vamorolone 0.25 mg/kg/day: Oral administration of 0.25 mg/kg/day daily for 14 days.</description>
          </group>
          <group group_id="O2">
            <title>Dose Level Group 2</title>
            <description>Participants enrolled in Dose Level Group 2 will receive vamorolone 0.75 mg/kg/day.
Vamorolone 0.75 mg/kg/day: Oral administration of 0.75 mg/kg/day daily for 14 days.</description>
          </group>
          <group group_id="O3">
            <title>Dose Level Group 3</title>
            <description>Participants enrolled in Dose Level Group 3 will receive vamorolone 2.0 mg/kg/day.
Vamorolone 2.0 mg/kg/day: Oral administration of 2.0 mg/kg/day daily for 14 days.</description>
          </group>
          <group group_id="O4">
            <title>Dose Level Group 4</title>
            <description>Participants enrolled in Dose Level Group 4 will receive vamorolone 6.0 mg/kg/day.
Vamorolone 6.0 mg/kg/day: Oral administration of 6 mg/kg/day daily for 14 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Pharmacodynamic Biomarkers (Bone Turnover)- Procollagen 1 N-Terminal Propeptide</title>
          <description>Pharmacodynamic biomarkers were measured to investigate the effects of single and multiple oral doses of vamorolone on serum PD biomarkers in ambulant boys ages 4-&lt; 7 years with DMD.</description>
          <population>Safety Population: All subjects who receive at least one dose of vamorolone study medication will be included in the Safety Population.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="555.8" spread="184.72"/>
                    <measurement group_id="O2" value="480.7" spread="118.20"/>
                    <measurement group_id="O3" value="508.2" spread="94.36"/>
                    <measurement group_id="O4" value="511.5" spread="106.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="12"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="474.0" spread="116.45"/>
                    <measurement group_id="O2" value="443.7" spread="112.38"/>
                    <measurement group_id="O3" value="417.1" spread="87.35"/>
                    <measurement group_id="O4" value="475.2" spread="147.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 Change from Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-81.8" spread="124.24"/>
                    <measurement group_id="O2" value="-34.5" spread="101.97"/>
                    <measurement group_id="O3" value="-91.1" spread="64.64"/>
                    <measurement group_id="O4" value="-36.5" spread="144.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="12"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="443.8" spread="93.86"/>
                    <measurement group_id="O2" value="407.8" spread="96.54"/>
                    <measurement group_id="O3" value="346.6" spread="68.59"/>
                    <measurement group_id="O4" value="303.7" spread="56.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2 Change from Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-112.0" spread="125.08"/>
                    <measurement group_id="O2" value="-70.6" spread="123.69"/>
                    <measurement group_id="O3" value="-161.6" spread="73.52"/>
                    <measurement group_id="O4" value="-207.8" spread="78.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="12"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="573.8" spread="251.02"/>
                    <measurement group_id="O2" value="496.7" spread="117.57"/>
                    <measurement group_id="O3" value="492.0" spread="81.92"/>
                    <measurement group_id="O4" value="566.3" spread="149.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 Change from Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.1" spread="153.10"/>
                    <measurement group_id="O2" value="21.3" spread="122.87"/>
                    <measurement group_id="O3" value="-16.2" spread="79.64"/>
                    <measurement group_id="O4" value="54.8" spread="118.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Treatment levels were not compared.</non_inferiority_desc>
            <other_analysis_desc>Safety Population was used for this analysis. Safety Population includes all subjects who receive at least one dose of vamorolone study medication.
Treatment levels were not compared.</other_analysis_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum Pharmacodynamic Biomarkers (Bone Turnover)- Procollagen 1 N-Terminal Propeptide</title>
        <description>Pharmacodynamic biomarkers were measured to investigate the effects of single and multiple oral doses of vamorolone on serum PD biomarkers in ambulant boys ages 4-&lt; 7 years with DMD.</description>
        <time_frame>Baseline, Day 1, Week 2, Week 4</time_frame>
        <population>Safety Population: All subjects who receive at least one dose of vamorolone study medication will be included in the Safety Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Dose Level Group 1</title>
            <description>Participants enrolled in Dose Level Group 1 will receive vamorolone 0.25 mg/kg/day.
Vamorolone 0.25 mg/kg/day: Oral administration of 0.25 mg/kg/day daily for 14 days.</description>
          </group>
          <group group_id="O2">
            <title>Dose Level Group 2</title>
            <description>Participants enrolled in Dose Level Group 2 will receive vamorolone 0.75 mg/kg/day.
Vamorolone 0.75 mg/kg/day: Oral administration of 0.75 mg/kg/day daily for 14 days.</description>
          </group>
          <group group_id="O3">
            <title>Dose Level Group 3</title>
            <description>Participants enrolled in Dose Level Group 3 will receive vamorolone 2.0 mg/kg/day.
Vamorolone 2.0 mg/kg/day: Oral administration of 2.0 mg/kg/day daily for 14 days.</description>
          </group>
          <group group_id="O4">
            <title>Dose Level Group 4</title>
            <description>Participants enrolled in Dose Level Group 4 will receive vamorolone 6.0 mg/kg/day.
Vamorolone 6.0 mg/kg/day: Oral administration of 6 mg/kg/day daily for 14 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Pharmacodynamic Biomarkers (Bone Turnover)- Procollagen 1 N-Terminal Propeptide</title>
          <description>Pharmacodynamic biomarkers were measured to investigate the effects of single and multiple oral doses of vamorolone on serum PD biomarkers in ambulant boys ages 4-&lt; 7 years with DMD.</description>
          <population>Safety Population: All subjects who receive at least one dose of vamorolone study medication will be included in the Safety Population.</population>
          <units>% change from Baseline</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1 Percent Change from Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.2" spread="17.07"/>
                    <measurement group_id="O2" value="-5.4" spread="24.58"/>
                    <measurement group_id="O3" value="-17.4" spread="12.59"/>
                    <measurement group_id="O4" value="-5.7" spread="30.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2 Percent Change from Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="12"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-17.5" spread="14.65"/>
                    <measurement group_id="O2" value="-11.2" spread="29.19"/>
                    <measurement group_id="O3" value="-30.9" spread="11.80"/>
                    <measurement group_id="O4" value="-39.9" spread="9.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 Percent Change from Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="12"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.8" spread="25.57"/>
                    <measurement group_id="O2" value="7.8" spread="30.86"/>
                    <measurement group_id="O3" value="-1.4" spread="17.47"/>
                    <measurement group_id="O4" value="11.8" spread="28.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum Pharmacodynamic Biomarkers (Bone Turnover)-Type I Collagen C-Telopeptides</title>
        <description>Pharmacodynamic biomarkers were measured to investigate the effects of single and multiple oral doses of vamorolone on serum PD biomarkers in ambulant boys ages 4-&lt; 7 years with DMD.</description>
        <time_frame>Baseline, Day 1, Week 4</time_frame>
        <population>Safety Population: All subjects who receive at least one dose of vamorolone study medication will be included in the Safety Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Dose Level Group 1</title>
            <description>Participants enrolled in Dose Level Group 1 will receive vamorolone 0.25 mg/kg/day.
Vamorolone 0.25 mg/kg/day: Oral administration of 0.25 mg/kg/day daily for 14 days.</description>
          </group>
          <group group_id="O2">
            <title>Dose Level Group 2</title>
            <description>Participants enrolled in Dose Level Group 2 will receive vamorolone 0.75 mg/kg/day.
Vamorolone 0.75 mg/kg/day: Oral administration of 0.75 mg/kg/day daily for 14 days.</description>
          </group>
          <group group_id="O3">
            <title>Dose Level Group 3</title>
            <description>Participants enrolled in Dose Level Group 3 will receive vamorolone 2.0 mg/kg/day.
Vamorolone 2.0 mg/kg/day: Oral administration of 2.0 mg/kg/day daily for 14 days.</description>
          </group>
          <group group_id="O4">
            <title>Dose Level Group 4</title>
            <description>Participants enrolled in Dose Level Group 4 will receive vamorolone 6.0 mg/kg/day.
Vamorolone 6.0 mg/kg/day: Oral administration of 6 mg/kg/day daily for 14 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Pharmacodynamic Biomarkers (Bone Turnover)-Type I Collagen C-Telopeptides</title>
          <description>Pharmacodynamic biomarkers were measured to investigate the effects of single and multiple oral doses of vamorolone on serum PD biomarkers in ambulant boys ages 4-&lt; 7 years with DMD.</description>
          <population>Safety Population: All subjects who receive at least one dose of vamorolone study medication will be included in the Safety Population.</population>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                    <count group_id="O2" value="12"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="871.0" spread="160.85"/>
                    <measurement group_id="O2" value="935.8" spread="286.50"/>
                    <measurement group_id="O3" value="936.8" spread="256.25"/>
                    <measurement group_id="O4" value="889.3" spread="186.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="12"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="974.8" spread="252.77"/>
                    <measurement group_id="O2" value="940.8" spread="227.60"/>
                    <measurement group_id="O3" value="838.3" spread="233.30"/>
                    <measurement group_id="O4" value="786.8" spread="331.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 Change from Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.4" spread="241.87"/>
                    <measurement group_id="O2" value="-12.9" spread="233.44"/>
                    <measurement group_id="O3" value="-98.5" spread="237.69"/>
                    <measurement group_id="O4" value="-115.7" spread="421.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="12"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="963.7" spread="157.68"/>
                    <measurement group_id="O2" value="903.3" spread="251.01"/>
                    <measurement group_id="O3" value="710.4" spread="180.03"/>
                    <measurement group_id="O4" value="625.7" spread="203.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2 Change from Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85.0" spread="185.90"/>
                    <measurement group_id="O2" value="-19.9" spread="266.99"/>
                    <measurement group_id="O3" value="-226.4" spread="185.99"/>
                    <measurement group_id="O4" value="-263.7" spread="229.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="12"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="915.9" spread="263.13"/>
                    <measurement group_id="O2" value="983.5" spread="298.47"/>
                    <measurement group_id="O3" value="949.8" spread="303.76"/>
                    <measurement group_id="O4" value="989.2" spread="216.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 Change from Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.4" spread="267.45"/>
                    <measurement group_id="O2" value="34.8" spread="271.50"/>
                    <measurement group_id="O3" value="12.9" spread="181.45"/>
                    <measurement group_id="O4" value="99.8" spread="211.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Treatment levels were not compared.</non_inferiority_desc>
            <other_analysis_desc>Safety Population was used for this analysis. Safety Population includes all subjects who receive at least one dose of vamorolone study medication.
Treatment levels were not compared.</other_analysis_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum Pharmacodynamic Biomarkers (Bone Turnover)-Type I Collagen C-Telopeptides</title>
        <description>Pharmacodynamic biomarkers were measured to investigate the effects of single and multiple oral doses of vamorolone on serum PD biomarkers in ambulant boys ages 4-&lt; 7 years with DMD.</description>
        <time_frame>Baseline, Day 1, Week 4</time_frame>
        <population>Safety Population: All subjects who receive at least one dose of vamorolone study medication will be included in the Safety Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Dose Level Group 1</title>
            <description>Participants enrolled in Dose Level Group 1 will receive vamorolone 0.25 mg/kg/day.
Vamorolone 0.25 mg/kg/day: Oral administration of 0.25 mg/kg/day daily for 14 days.</description>
          </group>
          <group group_id="O2">
            <title>Dose Level Group 2</title>
            <description>Participants enrolled in Dose Level Group 2 will receive vamorolone 0.75 mg/kg/day.
Vamorolone 0.75 mg/kg/day: Oral administration of 0.75 mg/kg/day daily for 14 days.</description>
          </group>
          <group group_id="O3">
            <title>Dose Level Group 3</title>
            <description>Participants enrolled in Dose Level Group 3 will receive vamorolone 2.0 mg/kg/day.
Vamorolone 2.0 mg/kg/day: Oral administration of 2.0 mg/kg/day daily for 14 days.</description>
          </group>
          <group group_id="O4">
            <title>Dose Level Group 4</title>
            <description>Participants enrolled in Dose Level Group 4 will receive vamorolone 6.0 mg/kg/day.
Vamorolone 6.0 mg/kg/day: Oral administration of 6 mg/kg/day daily for 14 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Pharmacodynamic Biomarkers (Bone Turnover)-Type I Collagen C-Telopeptides</title>
          <description>Pharmacodynamic biomarkers were measured to investigate the effects of single and multiple oral doses of vamorolone on serum PD biomarkers in ambulant boys ages 4-&lt; 7 years with DMD.</description>
          <population>Safety Population: All subjects who receive at least one dose of vamorolone study medication will be included in the Safety Population.</population>
          <units>% change from Baseline</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1 Percent Change from Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.9" spread="25.38"/>
                    <measurement group_id="O2" value="2.7" spread="23.76"/>
                    <measurement group_id="O3" value="-8.0" spread="23.93"/>
                    <measurement group_id="O4" value="-6.7" spread="53.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2 Percent Change from Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.9" spread="20.52"/>
                    <measurement group_id="O2" value="2.2" spread="26.44"/>
                    <measurement group_id="O3" value="-22.5" spread="15.27"/>
                    <measurement group_id="O4" value="-27.7" spread="26.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 Percent Change from Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.6" spread="28.96"/>
                    <measurement group_id="O2" value="6.8" spread="24.06"/>
                    <measurement group_id="O3" value="2.7" spread="19.03"/>
                    <measurement group_id="O4" value="14.5" spread="32.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetic (PK) Assessments (Tmax)</title>
        <description>Plasma concentrations of vamorolone were measured using a specific and validated liquid chromatography tandem mass spectrometry (LC-MS) assay. tmax= time when plasma concentration is at maximum.</description>
        <time_frame>Day 1, Week 2</time_frame>
        <population>All subjects who receive at least one dose of vamorolone study medication and have sufficient quantifiable plasma concentration data for PK analysis will be included in the PK population. [Note that the PK population will be determined by the study pharmacokineticist upon review of the concentration information for each subject in each cohort.</population>
        <group_list>
          <group group_id="O1">
            <title>Dose Level Group 1</title>
            <description>Participants enrolled in Dose Level Group 1 will receive vamorolone 0.25 mg/kg/day.
Vamorolone 0.25 mg/kg/day: Oral administration of 0.25 mg/kg/day daily for 14 days.</description>
          </group>
          <group group_id="O2">
            <title>Dose Level Group 2</title>
            <description>Participants enrolled in Dose Level Group 2 will receive vamorolone 0.75 mg/kg/day.
Vamorolone 0.75 mg/kg/day: Oral administration of 0.75 mg/kg/day daily for 14 days.</description>
          </group>
          <group group_id="O3">
            <title>Dose Level Group 3</title>
            <description>Participants enrolled in Dose Level Group 3 will receive vamorolone 2.0 mg/kg/day.
Vamorolone 2.0 mg/kg/day: Oral administration of 2.0 mg/kg/day daily for 14 days.</description>
          </group>
          <group group_id="O4">
            <title>Dose Level Group 4</title>
            <description>Participants enrolled in Dose Level Group 4 will receive vamorolone 6.0 mg/kg/day.
Vamorolone 6.0 mg/kg/day: Oral administration of 6 mg/kg/day daily for 14 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetic (PK) Assessments (Tmax)</title>
          <description>Plasma concentrations of vamorolone were measured using a specific and validated liquid chromatography tandem mass spectrometry (LC-MS) assay. tmax= time when plasma concentration is at maximum.</description>
          <population>All subjects who receive at least one dose of vamorolone study medication and have sufficient quantifiable plasma concentration data for PK analysis will be included in the PK population. [Note that the PK population will be determined by the study pharmacokineticist upon review of the concentration information for each subject in each cohort.</population>
          <units>hour</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.6" spread="1.2"/>
                    <measurement group_id="O2" value="4.6" spread="2.1"/>
                    <measurement group_id="O3" value="2.5" spread="1.3"/>
                    <measurement group_id="O4" value="2.7" spread="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.8" spread="1.80"/>
                    <measurement group_id="O2" value="3.8" spread="2.2"/>
                    <measurement group_id="O3" value="2.8" spread="1"/>
                    <measurement group_id="O4" value="2.3" spread="0.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetic (PK) Assessments (AUC Inf)</title>
        <description>Plasma concentrations of vamorolone were measured using a specific and validated liquid chromatography tandem mass spectrometry (LC-MS) assay. AUC inf= Area under the concentration vs. time curve to time infinity.</description>
        <time_frame>Day 1, Week 2</time_frame>
        <population>All subjects who receive at least one dose of vamorolone study medication and have sufficient quantifiable plasma concentration data for PK analysis will be included in the PK population. [Note that the PK population will be determined by the study pharmacokineticist upon review of the concentration information for each subject in each cohort.</population>
        <group_list>
          <group group_id="O1">
            <title>Dose Level Group 1</title>
            <description>Participants enrolled in Dose Level Group 1 will receive vamorolone 0.25 mg/kg/day.
Vamorolone 0.25 mg/kg/day: Oral administration of 0.25 mg/kg/day daily for 14 days.</description>
          </group>
          <group group_id="O2">
            <title>Dose Level Group 2</title>
            <description>Participants enrolled in Dose Level Group 2 will receive vamorolone 0.75 mg/kg/day.
Vamorolone 0.75 mg/kg/day: Oral administration of 0.75 mg/kg/day daily for 14 days.</description>
          </group>
          <group group_id="O3">
            <title>Dose Level Group 3</title>
            <description>Participants enrolled in Dose Level Group 3 will receive vamorolone 2.0 mg/kg/day.
Vamorolone 2.0 mg/kg/day: Oral administration of 2.0 mg/kg/day daily for 14 days.</description>
          </group>
          <group group_id="O4">
            <title>Dose Level Group 4</title>
            <description>Participants enrolled in Dose Level Group 4 will receive vamorolone 6.0 mg/kg/day.
Vamorolone 6.0 mg/kg/day: Oral administration of 6 mg/kg/day daily for 14 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetic (PK) Assessments (AUC Inf)</title>
          <description>Plasma concentrations of vamorolone were measured using a specific and validated liquid chromatography tandem mass spectrometry (LC-MS) assay. AUC inf= Area under the concentration vs. time curve to time infinity.</description>
          <population>All subjects who receive at least one dose of vamorolone study medication and have sufficient quantifiable plasma concentration data for PK analysis will be included in the PK population. [Note that the PK population will be determined by the study pharmacokineticist upon review of the concentration information for each subject in each cohort.</population>
          <units>[(hr)(ng)/mL]</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="118" spread="48"/>
                    <measurement group_id="O2" value="379" spread="117"/>
                    <measurement group_id="O3" value="761" spread="352"/>
                    <measurement group_id="O4" value="3279" spread="1693"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="164" spread="61"/>
                    <measurement group_id="O2" value="544" spread="155"/>
                    <measurement group_id="O3" value="1138" spread="467"/>
                    <measurement group_id="O4" value="3606" spread="897"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetic (PK) Assessments CL (ml/hr/kg)</title>
        <description>Plasma concentrations of vamorolone were measured using a specific and validated liquid chromatography tandem mass spectrometry (LC-MS) assay</description>
        <time_frame>Day 1, Week 2</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Dose Level Group 1</title>
            <description>Participants enrolled in Dose Level Group 1 will receive vamorolone 0.25 mg/kg/day.
Vamorolone 0.25 mg/kg/day: Oral administration of 0.25 mg/kg/day daily for 14 days.</description>
          </group>
          <group group_id="O2">
            <title>Dose Level Group 2</title>
            <description>Participants enrolled in Dose Level Group 2 will receive vamorolone 0.75 mg/kg/day.
Vamorolone 0.75 mg/kg/day: Oral administration of 0.75 mg/kg/day daily for 14 days.</description>
          </group>
          <group group_id="O3">
            <title>Dose Level Group 3</title>
            <description>Participants enrolled in Dose Level Group 3 will receive vamorolone 2.0 mg/kg/day.
Vamorolone 2.0 mg/kg/day: Oral administration of 2.0 mg/kg/day daily for 14 days.</description>
          </group>
          <group group_id="O4">
            <title>Dose Level Group 4</title>
            <description>Participants enrolled in Dose Level Group 4 will receive vamorolone 6.0 mg/kg/day.
Vamorolone 6.0 mg/kg/day: Oral administration of 6 mg/kg/day daily for 14 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetic (PK) Assessments CL (ml/hr/kg)</title>
          <description>Plasma concentrations of vamorolone were measured using a specific and validated liquid chromatography tandem mass spectrometry (LC-MS) assay</description>
          <units>ml/hr/kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2459" spread="897"/>
                    <measurement group_id="O2" value="2285" spread="1103"/>
                    <measurement group_id="O3" value="2697" spread="1285"/>
                    <measurement group_id="O4" value="2320" spread="1375"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1828" spread="919"/>
                    <measurement group_id="O2" value="1509" spread="482"/>
                    <measurement group_id="O3" value="2047" spread="771"/>
                    <measurement group_id="O4" value="1777" spread="476"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetic (PK) Assessments t(1/2)</title>
        <description>Plasma concentrations of vamorolone were measured using a specific and validated liquid chromatography tandem mass spectrometry (LC-MS) assay. t1/2= elimination half life.</description>
        <time_frame>Day 1, Week 2</time_frame>
        <population>All subjects who receive at least one dose of vamorolone study medication and have sufficient quantifiable plasma concentration data for PK analysis will be included in the PK population. [Note that the PK population will be determined by the study pharmacokineticist upon review of the concentration information for each subject in each cohort.</population>
        <group_list>
          <group group_id="O1">
            <title>Dose Level Group 1</title>
            <description>Participants enrolled in Dose Level Group 1 will receive vamorolone 0.25 mg/kg/day.
Vamorolone 0.25 mg/kg/day: Oral administration of 0.25 mg/kg/day daily for 14 days.</description>
          </group>
          <group group_id="O2">
            <title>Dose Level Group 2</title>
            <description>Participants enrolled in Dose Level Group 2 will receive vamorolone 0.75 mg/kg/day.
Vamorolone 0.75 mg/kg/day: Oral administration of 0.75 mg/kg/day daily for 14 days.</description>
          </group>
          <group group_id="O3">
            <title>Dose Level Group 3</title>
            <description>Participants enrolled in Dose Level Group 3 will receive vamorolone 2.0 mg/kg/day.
Vamorolone 2.0 mg/kg/day: Oral administration of 2.0 mg/kg/day daily for 14 days.</description>
          </group>
          <group group_id="O4">
            <title>Dose Level Group 4</title>
            <description>Participants enrolled in Dose Level Group 4 will receive vamorolone 6.0 mg/kg/day.
Vamorolone 6.0 mg/kg/day: Oral administration of 6 mg/kg/day daily for 14 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetic (PK) Assessments t(1/2)</title>
          <description>Plasma concentrations of vamorolone were measured using a specific and validated liquid chromatography tandem mass spectrometry (LC-MS) assay. t1/2= elimination half life.</description>
          <population>All subjects who receive at least one dose of vamorolone study medication and have sufficient quantifiable plasma concentration data for PK analysis will be included in the PK population. [Note that the PK population will be determined by the study pharmacokineticist upon review of the concentration information for each subject in each cohort.</population>
          <units>hour</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.1" spread="0.85"/>
                    <measurement group_id="O2" value="1.8" spread="0.43"/>
                    <measurement group_id="O3" value="1.9" spread="0.79"/>
                    <measurement group_id="O4" value="1.9" spread="0.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.9" spread="0.96"/>
                    <measurement group_id="O2" value="2.1" spread="0.8"/>
                    <measurement group_id="O3" value="1.9" spread="1.02"/>
                    <measurement group_id="O4" value="1.4" spread="0.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetic (PK) Assessments (Cmax)</title>
        <description>Plasma concentrations of vamorolone were measured using a specific and validated liquid chromatography tandem mass spectrometry (LC-MS) assay</description>
        <time_frame>Day 1, Week 2</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Dose Level Group 1</title>
            <description>Participants enrolled in Dose Level Group 1 will receive vamorolone 0.25 mg/kg/day.
Vamorolone 0.25 mg/kg/day: Oral administration of 0.25 mg/kg/day daily for 14 days.</description>
          </group>
          <group group_id="O2">
            <title>Dose Level Group 2</title>
            <description>Participants enrolled in Dose Level Group 2 will receive vamorolone 0.75 mg/kg/day.
Vamorolone 0.75 mg/kg/day: Oral administration of 0.75 mg/kg/day daily for 14 days.</description>
          </group>
          <group group_id="O3">
            <title>Dose Level Group 3</title>
            <description>Participants enrolled in Dose Level Group 3 will receive vamorolone 2.0 mg/kg/day.
Vamorolone 2.0 mg/kg/day: Oral administration of 2.0 mg/kg/day daily for 14 days.</description>
          </group>
          <group group_id="O4">
            <title>Dose Level Group 4</title>
            <description>Participants enrolled in Dose Level Group 4 will receive vamorolone 6.0 mg/kg/day.
Vamorolone 6.0 mg/kg/day: Oral administration of 6 mg/kg/day daily for 14 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetic (PK) Assessments (Cmax)</title>
          <description>Plasma concentrations of vamorolone were measured using a specific and validated liquid chromatography tandem mass spectrometry (LC-MS) assay</description>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.9" spread="13.4"/>
                    <measurement group_id="O2" value="75.9" spread="25.9"/>
                    <measurement group_id="O3" value="199" spread="111"/>
                    <measurement group_id="O4" value="855.6" spread="471"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.2" spread="15.2"/>
                    <measurement group_id="O2" value="124.7" spread="42.5"/>
                    <measurement group_id="O3" value="252.2" spread="96"/>
                    <measurement group_id="O4" value="970" spread="270"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Metabolites in Safety Testing (MIST) Assessment</title>
        <description>A portion of each blood sample of the Week 2 (Day 14) pharmacokinetic assessment time points for the subjects receiving vamorolone 2 mg/kg/day was used for analysis of vamorolone metabolites.</description>
        <time_frame>Week 2 (Day 14)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Dose Level Group 3</title>
            <description>Participants enrolled in Dose Level Group 3 will receive vamorolone 2.0 mg/kg/day.
Vamorolone 2.0 mg/kg/day: Oral administration of 2.0 mg/kg/day daily for 14 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Metabolites in Safety Testing (MIST) Assessment</title>
          <description>A portion of each blood sample of the Week 2 (Day 14) pharmacokinetic assessment time points for the subjects receiving vamorolone 2 mg/kg/day was used for analysis of vamorolone metabolites.</description>
          <units>% of total drug related exposure</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>M1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.42" spread="2.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.16" spread="0.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.21" spread="0.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.84" spread="3.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.73" spread="0.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vamorolone</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.64" spread="0.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events will be recorded from the date of informed consent and through the time of the subject’s last study visit. Serious adverse events will be recorded from the date of informed consent and for up to 30 days after final drug administration.</time_frame>
      <desc>The incidence of TEAEs will be summarized by dose level, SOC and preferred term; dose level, SOC, and intensity (CTCAE grade; CTCAE version 4.03); dose level, SOC, and outcome; and dose level, SOC and relationship to study drug.</desc>
      <group_list>
        <group group_id="E1">
          <title>Dose Level Group 1</title>
          <description>Participants enrolled in Dose Level Group 1 will receive vamorolone 0.25 mg/kg/day.
Vamorolone 0.25 mg/kg/day: Oral administration of 0.25 mg/kg/day daily for 14 days.</description>
        </group>
        <group group_id="E2">
          <title>Dose Level Group 2</title>
          <description>Participants enrolled in Dose Level Group 2 will receive vamorolone 0.75 mg/kg/day.
Vamorolone 0.75 mg/kg/day: Oral administration of 0.75 mg/kg/day daily for 14 days.</description>
        </group>
        <group group_id="E3">
          <title>Dose Level Group 3</title>
          <description>Participants enrolled in Dose Level Group 3 will receive vamorolone 2.0 mg/kg/day.
Vamorolone 2.0 mg/kg/day: Oral administration of 2.0 mg/kg/day daily for 14 days.</description>
        </group>
        <group group_id="E4">
          <title>Dose Level Group 4</title>
          <description>Participants enrolled in Dose Level Group 4 will receive vamorolone 6.0 mg/kg/day.
Vamorolone 6.0 mg/kg/day: Oral administration of 6 mg/kg/day daily for 14 days.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 18.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Abdominal Pain Upper</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Faeces Discoloured</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Lip Swelling</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Enterobiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Lice Infestation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Viral Upper Respiratory Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscle Spasms</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Pain in Extremity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Lethargy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Agitation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Emotional Disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Restlessness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Chromaturia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Upper-airway cough syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Rash Macular</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Eric P. Hoffman</name_or_title>
      <organization>ReveraGen Biopharma Inc.</organization>
      <phone>240-672-0295</phone>
      <email>ericphoffman@gmail.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

